Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use-Reference-Cited by-同舟云学术

Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use

Published:2023-03-21 Issue:3 Volume:11 Page:707
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Wichgers Schreur Paul J.¹²^ORCID,Bird Brian H.³,Ikegami Tetsuro⁴⁵⁶^ORCID,Bermúdez-Méndez Erick¹⁷,Kortekaas Jeroen¹⁷

Affiliation:

1. Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The Netherlands

2. BunyaVax B.V., 8221 RA Lelystad, The Netherlands

3. One Health Institute, School of Veterinary Medicine, University of California, Davis, CA 95616, USA

4. Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA

5. The Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA

6. The Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA

7. Laboratory of Virology, Wageningen University & Research, 6708 PB Wageningen, The Netherlands

Abstract

Live-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with classical live-attenuated RVF vaccines during gestation in livestock has been associated with fetal malformations, stillbirths, and fetal demise. Facilitated by an increased understanding of the RVFV infection and replication cycle and availability of reverse genetics systems, novel rationally-designed live-attenuated candidate RVF vaccines with improved safety profiles have been developed. Several of these experimental vaccines are currently advancing beyond the proof-of-concept phase and are being evaluated for application in both animals and humans. We here provide perspectives on some of these next-generation live-attenuated RVF vaccines and highlight the opportunities and challenges of these approaches to improve global health.

Funder

CEPI

Graduate School of Production Ecology & Resource Conservation

Universidad de Costa Rica

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/3/707/pdf

Reference83 articles.

1. The challenging management of Rift Valley Fever in humans: Literature review of the clinical disease and algorithm proposal;Javelle;Ann. Clin. Microbiol. Antimicrob.,2020

2. Scoping future outbreaks: A scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases;Jonkmans;BMJ Glob. Health,2021

3. Rift Valley fever virus: Strategies for maintenance, survival and vertical transmission in mosquitoes;Lumley;J. Gen. Virol.,2017

4. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine;Smithburn;Br. J. Exp. Pathol.,1949

5. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine;Botros;J. Med. Virol.,2006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computer-Selected Antiviral Compounds: Assessing In Vitro Efficacies against Rift Valley Fever Virus;Viruses;2024-01-05

2. Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus;Viruses;2024-01-05

3. Humoral immunity to phlebovirus infection;Annals of the New York Academy of Sciences;2023-11-07

4. The increasing threat of Rift Valley fever virus globalization: strategic guidance for protection and preparation;Journal of Medical Entomology;2023-10-20